These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 1659174

  • 1. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
    Gatzemeier U, Heckmayr M, Hossfeld DK, Kaukel E, Koschel G, Neuhauss R.
    Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174
    [Abstract] [Full Text] [Related]

  • 2. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
    Gatzemeier U, Heckmayr M, Hossfeld DK, Kaukel E, Koschel G, Neuhauss R.
    Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
    [Abstract] [Full Text] [Related]

  • 3. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M.
    Cancer; 1990 Apr 15; 65(8):1692-9. PubMed ID: 2156597
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C.
    Ann Oncol; 1995 Apr 15; 6(4):347-53. PubMed ID: 7619749
    [Abstract] [Full Text] [Related]

  • 5. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct 15; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

  • 6. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
    Crinò L, Clerici M, Figoli F, Barduagni M, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F.
    Lung Cancer; 1995 Apr 15; 12 Suppl 1():S125-32. PubMed ID: 7551920
    [Abstract] [Full Text] [Related]

  • 7. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
    Masutani M, Akusawa H, Kadota A, Ohchi Y, Takahashi N, Tanigawa S, Koya Y, Horie T.
    Respirology; 1996 Mar 15; 1(1):49-54. PubMed ID: 9432405
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M.
    J Clin Oncol; 1991 Apr 15; 9(4):606-13. PubMed ID: 1648597
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
    González Barón M, Artal A, Garrido P, García Girón C, Ordóñez A, Feliu J, Berrocal A, Barón JM.
    Am J Clin Oncol; 1993 Aug 15; 16(4):310-4. PubMed ID: 8392287
    [Abstract] [Full Text] [Related]

  • 10. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Cok G, Göksel T, Soyer S, Atil H, Güzelant A, Aysan T.
    Tuberk Toraks; 2006 Aug 15; 54(2):161-7. PubMed ID: 16924573
    [Abstract] [Full Text] [Related]

  • 11. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M, Kiura K, Okabe K, Toki H, Kimura M.
    Gan To Kagaku Ryoho; 1987 Sep 15; 14(9):2676-81. PubMed ID: 2820312
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusunoki Y, Matsui K, Masuda N, Ryu S, Sakai N, Kubota K.
    Gan To Kagaku Ryoho; 1990 Mar 15; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
    González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordóñez A, Moyano A, de la Gándara I.
    Ann Oncol; 1994 Apr 15; 5(4):323-7. PubMed ID: 8075028
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R.
    Br J Cancer; 1998 Jun 15; 77(12):2367-70. PubMed ID: 9649160
    [Abstract] [Full Text] [Related]

  • 16. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
    Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y, Moritaka T, Hiraki S, Harada M, Tanimoto M.
    Lung Cancer; 2002 Jun 15; 36(3):313-9. PubMed ID: 12009244
    [Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
    Stockler M, Raghavan D, McCaughan BC, Grygiel J, McNeil E, Gianoutsos P, Lee JH.
    Med J Aust; 1992 May 18; 156(10):698-700. PubMed ID: 1377770
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Vansteenkiste J, Vandebroek J, Mariën S, Roex L, Bertrand P, Bockaert J, De Beukelaar T, Deman R, De Muynck P, Ulrichts H.
    Lung Cancer; 1995 Dec 18; 13(3):295-303. PubMed ID: 8719069
    [Abstract] [Full Text] [Related]

  • 20. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J.
    Br J Cancer; 2000 Nov 18; 83(9):1128-35. PubMed ID: 11027424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.